Back in 2024 Goldfinch Bios received a 750 million dollar AUD licence agreement after phase 1 completion of their TRPC 4/5 inhibitor. NYR is having a first in class TRPC 3,6,7 inhibitor it’s exciting to see what happens after phase 1 in the next 1-2 months and how revolutionary this will become in the TBI, stroke and heart attack space. 25 million market cap going a lot higher
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.030(11.5%) |
Mkt cap ! $48.51M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 23.0¢ | $99.69K | 416.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31363 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 68238 | 2 |
View Market Depth
| Last trade - 12.47pm 19/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |